UBER - Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger Novo Nordisk's Weight Loss Drugs May Pose Serious Stomach Risks Netflix's Local Content and Pricing Woes Undermine Growth in India: Today's Top Stories | Benzinga
Bloomberg
Regulatory Shadow Over Saudi Golf League LIV And PGA Tour Merger
- The merger between the PGA Tour and Saudi-backed LIV Golf, initially set to be finalized by December 31, faces potential delays amid regulatory concerns in the U.S. and demands by PGA Tour players for a stake.
- The players, guided by the Raine Group, are instrumental in the ongoing negotiations, underscoring a shift from earlier discussions that excluded them.
Snapchat's AI Chatbot Faces UK Regulatory Hurdle Over Privacy Concerns
- The U.K.'s Information Commissioner's Office (ICO) has handed a preliminary enforcement notice to Snap Inc (NYSE: SNAP), the company behind Snapchat, due to concerns regarding privacy risks associated with its My AI chatbot.
- The ICO's investigation has provisionally found that Snap may not have sufficiently identified and assessed privacy risks to children and other users before launching the chatbot.
Benzinga
Philips' Ventilator Device Recall Faces FDA's Continued Discontent Pressure
- In its latest update on Koninklijke Philips NV's (NYSE: PHG) Respironics' June 2021 recall of certain CPAP, BiPAP, and ventilator devices, the FDA highlights ongoing concerns about the potential health risks from the devices' foam degradation.
- The update from Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, says the FDA "remains unsatisfied" with the recall status and that Philips' testing to date is inadequate.
Micron's $15B Investment Promises Economic and Technological Renaissance with New Idaho Facility
- Micron Technology, Inc (NASDAQ: MU) recently marked the commencement of construction on a pioneering memory manufacturing facility in Boise, Idaho.
- The new fab, representing an investment of approximately $15 billion, will likely inject $15.3 billion into the Idaho economy, create over 17,000 jobs, and foster a skilled, diverse workforce.
Novo Nordisk's Weight Loss Drugs Like Wegovy, Ozempic May Pose Serious Stomach Risks, Study Suggests
- A recent study published in JAMA has raised concerns about the potential risks associated with popular weight loss and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO), Wegovy (semaglutide), Ozempic (semaglutide), and Saxenda (liraglutide).
- The study suggests that these drugs, known ...